Zhang Yi, Du Hui, Xiao Aimin, Zhang Wei, Wang Chun, Huang Xia, Qu Xinfeng, Wang Jianliu, Wu Ruifang
Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, 518036, People's Republic of China.
Institute of Obstetrics and Gynecology, Shenzhen PKU-HKUST Medical Center, Shenzhen, 518036, People's Republic of China.
Infect Agent Cancer. 2022 Jun 11;17(1):27. doi: 10.1186/s13027-022-00440-4.
To verify the association of high-risk human papillomavirus (hrHPV) viral load reflected by cycle threshold (Ct) values from HPV testing on Cobas4800 assay with the histologic grades of cervical lesions via analysis on the combined data from two cervical cancer screening trials and to explore the referability of Ct values in management of the abnormalities from cervical cancer primary screening.
We analyzed the data from Chinese Multi-Center Screening Trial (CHMUST) and BUJI Cervical Cancer Screening Study Project (BUJI Study). All data to be analyzed in this paper were related to provider-collected samples. One-way ANOVA was performed to compare the Ct values among different histological groups, and Kendall's tau-b correlation was applied to examine the association between Ct values and cervical lesion grades. The stepwise incidence of CIN2+ and CIN3+ in every 100 HPV positive individuals were calculated according to the descending of the genotype specific Ct values. The highest Ct values related to CIN3+ incidence rate 4% (or 25%) were used as the cutoffs to distinguish low-Ct value cases from the high-Ct value ones.
A total of 1376 women in CHUMUST and BUJI Study who were aged 30-59 and positive of hrHPV for provider-collected samples on Cobas4800 with complete data in terms of the relevant Ct values (CtV) and the histological diagnosis were included for analysis. Our data showed significant difference among different histological grades of cervical lesions in the CtV of hrHPV, HPV16-plus (positive of HPV16 only or HPV16 plus 18 and/or pooled 12-HPV), and pooled 12-HPV (P < 0.05). No significant difference was found among different grades of lesions in term of correlated CtV of HPV18-plus (positive of HPV18 only or HPV18 plus pooled 12-HPV) (P > 0.05). The CIN2+ or CIN3+ incidence per 100 positives significantly increased corresponding to the descending of the CtV of hrHPV, HPV16-plus and pooled 12-HPV. Compared with high-CtV groups (CtV > 33.2 for hrHPV, CtV > 29.6 for pooled 12-HPV), the relevant risks (RRs) of CIN2+ for hrHPV and pooled 12-HPV positive groups with low-CtV (CtV ≤ 33.2 and ≤ 29.6, respectively) were 3.2 (95%CI 2.18-4.80) and 2.3 (95%CI 1.50-3.45). Similarly, the RRs of CIN3+ for hrHPV and pooled 12-HPV positive groups with low-CtV were 6.5 (95%CI 2.83-14.80) and 2.7 (95%CI 1.15-6.39), respectively. The RRs of CIN2+ for medium- (30.3 < CtV ≤ 37.4) and low- (≤ 30.3) CtV HPV16-plus positives were 5.1 (95%CI 0.68-38.38) and 20.6 (95%CI 2.96-143.92) related to high-CtV (> 37.4) groups, and the CIN3+ incidence in low-CtV value group was nine-fold higher of that in medium-CtV ones [RRs, 9.0 (95%CI 2.89-28.10)]. In comparing with the algorithms of "HPV16-plus/18-plus + cytology ≥ ASCUS for pooled 12-HPV", triage algorithm "HPV16-plus/18-plus + Ct value ≤ 33.2 for pooled 12-HPV" could achieve a comparable sensitivity of 93.2%.
HPV viral loads reflected by Ct values for hrHPV, HPV16-plus and pooled 12-HPV from Cobas4800 HPV testing were directly associated with the severity of cervical lesions. A lower HPV genotype-specific Ct value prompted a significantly high CIN3+ risk of 4% or higher in women positive of hrHPV, HPV16-plus or pooled 12-HPV, indicating that HPV viral load reflected by Ct values on Cobas4800 may be a promising risk indicator in management of abnormalities from primary cervical cancer screening.
通过对两项宫颈癌筛查试验的合并数据进行分析,验证Cobas4800检测中HPV检测的循环阈值(Ct)值所反映的高危型人乳头瘤病毒(hrHPV)病毒载量与宫颈病变组织学分级之间的关联,并探讨Ct值在宫颈癌初筛异常管理中的参考价值。
我们分析了中国多中心筛查试验(CHMUST)和布吉宫颈癌筛查研究项目(布吉研究)的数据。本文所有待分析数据均与医疗机构采集的样本有关。采用单因素方差分析比较不同组织学组的Ct值,并应用肯德尔tau-b相关性分析检验Ct值与宫颈病变分级之间的关联。根据基因型特异性Ct值的降序计算每100例HPV阳性个体中CIN2+和CIN3+的逐步发病率。将与CIN3+发病率4%(或25%)相关的最高Ct值用作区分低Ct值病例和高Ct值病例的临界值。
CHUMUST和布吉研究中共有1376名年龄在30-59岁之间、Cobas4800检测医疗机构采集样本hrHPV阳性且具有完整相关Ct值(CtV)和组织学诊断数据的女性纳入分析。我们的数据显示,hrHPV、HPV16加(仅HPV16阳性或HPV16加18和/或12种合并HPV阳性)和12种合并HPV的CtV在不同组织学分级的宫颈病变之间存在显著差异(P<0.05)。HPV18加(仅HPV18阳性或HPV18加12种合并HPV阳性)的相关CtV在不同分级病变之间未发现显著差异(P>0.05)。每100例阳性个体中CIN2+或CIN3+的发病率随着hrHPV、HPV16加和12种合并HPV的CtV的降低而显著增加。与高CtV组(hrHPV的CtV>33.2,12种合并HPV的CtV>29.6)相比,hrHPV和12种合并HPV低CtV(分别为CtV≤33.2和≤29.6)阳性组CIN2+的相关风险(RRs)分别为3.2(95%CI 2.18-4.80)和2.3(95%CI 1.50-3.45)。同样,hrHPV和12种合并HPV低CtV阳性组CIN3+的RRs分别为6.5(95%CI 2.83-14.80)和2.7(95%CI 1.15-6.39)。中(30.3<CtV≤37.4)低(≤30.3)CtV的HPV16加阳性个体CIN2+的RRs与高CtV(>37.4)组相比分别为5.1(95%CI 0.68-38.38)和20.6(95%CI 2.96-143.92),低CtV值组CIN3+发病率是中CtV组的9倍[RRs,9.0(95%CI 2.89-28.10)]。与“HPV16加/18加+细胞学≥ASCUS用于12种合并HPV”算法相比,“HPV16加/18加+Ct值≤33.2用于12种合并HPV”的分流算法可实现93.2%的可比灵敏度。
Cobas4800 HPV检测中hrHPV、HPV16加和12种合并HPV的Ct值所反映出的HPV病毒载量与宫颈病变的严重程度直接相关。hrHPV、HPV16加或12种合并HPV阳性女性中,较低的HPV基因型特异性Ct值提示CIN3+风险显著升高至4%或更高,这表明Cobas4800检测中Ct值所反映的HPV病毒载量可能是宫颈癌初筛异常管理中有前景的风险指标。